A Study of Telisotuzumab Adizutecan (ABBV-400) in People With Solid Tumor Cancer

Full Title

A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects with Locally Advanced or Metastatic Solid Tumors that Harbor MET Amplification

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Yonina Murciano-Goroff’s office at 646-888-4226.

Protocol
25-360
Phase
Phase II (phase 2)
Disease Status
Relapsed or Refractory
Co-Investigators
ClinicalTrials.gov ID
NCT07196644